Although CHIP mutations cannot “drive” tumor growth, it is possible that secondary mutations in clonally expanding immune cells could affect their anti-tumor activity, potentially “facilitating” or indirectly increasing the risk of tumor growth. This evidence concerns the gene STUB1 and neoplasm.